Table 4. Safety investigation results in the participants of the placebo and WS groups.

WS=Ashwagandha, P=placebo

*Represents p<0.05 between day seven and day 60 of the placebo group on the paired T-test;

#Represents p<0.05 between day seven and day 60 of the WS group on the paired T-test;

$represents p<0.05 between the placebo and WS groups on the unpaired T-test

No.	Variable	Day -7 (screening) Mean ± SD		Day 60 Mean ± SD
		P n=24	WS n=27	P n=24	WS n=27
1	RBC (million/mm3)	5.01 ± 0.5	4.79 ± 0.5	9.84 ± 13.72	7.56 ± 10.35
2	WBC (million/mm3)	6912 ± 1847.9	7672.2 ± 1797.5	7059.6 ± 1324.02	6584.81 ± 1645.38
3	Polymorphs (%)	60.96 ± 4.97	63.85 ± 5.36	62.8 ± 4.85	63.7 ± 4.61
4	Lymphocytes (%)	38.48 ± 5.29	35.37 ±4.8$	36.92 ± 3.93	35.04 ± 4.75
5	Monocytes (%)	0.12 ± 0.44	0.15 ± 0.36	0.28 ± 0.61	0.3 ± 0.87
6	Fasting blood sugar [FBS] (mg/dL)	88.1 ± 7.95	90.69 ± 6.98	91.06 ±9.5	92.4 ± 7.87
7	Serum cholesterol(mg/dL)	113.5 ± 60.96	108.9 ± 65.82	172.04 ± 33.7*	178.24 ± 47.4#
8	Serum triglyceride(mg/dL)	99.18 ± 29.26	95.57 ± 29.61	106.3 ± 48.17	111.47± 67.85
9	SGPT(IU/L)	21.6 ± 11.73	26.9 ± 11.8	21.61 ± 11.56	26.4± 11.89
10	SGOT(IU/L)	23.5 ± 5.8	25.46 ± 5.98	23.3 ± 5.4	26.8 ± 8.34
11	Serum creatinine (mg/dL)	0.95 ± 0.17	0.96 ± 0.16	0.98 ± 0.2	0.89 ± 0.22
12	Blood urea nitrogen(mg/dL)	10.41 ± 2.42	10.84 ± 3.28	12.04 ± 3.87	12.53 ± 6.01